Literature DB >> 3924872

Novel antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721. Taxonomy, fermentation and biological activity.

J B Tunac, B D Graham, W E Dobson, M D Lenzini.   

Abstract

The novel, broad-spectrum antitumor antibiotics, CI-940 (PD 114,720) and PD 114,721 are components of bioactive compounds produced by a novel actinomycete (ATCC 39366). The organism is unique in that whole cell analysis revealed LL-diaminopimelic acid and major amounts of arabinose. These new antibiotics exhibit potent antitumor activity in vitro and in vivo versus an array of tumors and possess strong antibacterial and antifungal activity. The above antibiotics are produced in 7,570-liter fermentors at yields of 5 approximately 8 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924872     DOI: 10.7164/antibiotics.38.460

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  4 in total

1.  In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).

Authors:  B J Roberts; K L Hamelehle; J S Sebolt; W R Leopold
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Phase I trial of elactocin.

Authors:  E S Newlands; G J Rustin; M H Brampton
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

3.  Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.

Authors:  Meghan M Cromie; Weimin Gao
Journal:  Oxid Med Cell Longev       Date:  2015-04-01       Impact factor: 6.543

4.  Metabolomic Profiles of the Creeping Wood Sorrel Oxalis corniculata in Radioactively Contaminated Fields in Fukushima: Dose-Dependent Changes in Key Metabolites.

Authors:  Ko Sakauchi; Wataru Taira; Joji M Otaki
Journal:  Life (Basel)       Date:  2022-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.